SERVİKAL YÜKSEK DERECELİ SKUAMOZ İNTRAEPİTELYAL LEZYON İÇİN DE⁄ERLENDİRME SIRASINDA İNSİDENTAL OLARAK SAPTANAN İLERİ EVRE UTERİN LEİOMYOSARKOM: OLGU SUNUMU

Öz

Uterin leiomyosarkom (LMS), kadın genital yol maligniteleri arasında nadir olarak saptanan ve endometrium kanserine göre daha agresif seyirli tümörlerdir. Diğer kanserlerde olduğu gibi, erken tanı prognoza olumlu katkı sağlar. Hastalarda genellikle postmenopozal vajinal kanama veya karın ağrısı gibi semptomlar bulunmakla beraber, tamamen asemptomatik olgularla da karşılaşılabilir. Bu yazıda, servikste yüksek dereceli skuamoz intraepitelyal lezyon (HSIL) nedeniyle refere edilen, ayrıntılı inceleme neticesinde ileri evre LMS saptanan bir olgu sunulmaktadı

Anahtar Kelimeler

• Uterin Leiomyosarkom, Yüksek Dereceli Skuamoz İntraepitelyal Lezyon, HSIL, Postmenopozal Kanama.

Öz

Uterin leiomyosarcoma (LMS) is a rare female genital tract malignancy with an aggressive clinical course with respect to endometrial cancer. Early diagnosis is associated with a more favorable prognosis. Although patients generally present with symptoms such as postmenopausal bleeding and pelvic pain, entirely asymptomatic cases may also be encountered. In this paper, a case that was initially referred for high grade squamous intraepithelial lesion of the cervix, consequently diagnosed with advanced stage LMS after detailed examination is reported

Anahtar Kelimeler

• Uterine Leiomyosarcoma, High Grade Squamous Intraepithelial Lesion, HSIL, Postmenopausal Bleeding.

Kaynakça

1. 1. Forney JP, Buschbaum HJ. Classifying, staging, and treating uterine sarcomas. Contemp Ob Gyn. 1981;18(3):47.
2. 2. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188-98. Epub 2009/12/05.
3. 3. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet. 2000;356(9233):881-7. Epub 2000/10/19.
4. 4. Leibsohn S, d’Ablaing G, Mishell DR, Jr., Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162(4):968-74; discussion 74-6. Epub 1990/04/01.
5. 5. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer. 1989;63(5):935-8. Epub 1989/03/01.
6. 6. Bartsich EG, Bowe ET, Moore JG. Leiomyosarcoma of the uterus. A 50-year review of 42 cases. Obstet Gynecol. 1968;32(1):101-6. Epub 1968/07/01.
7. 7. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in earlystage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71(4 Suppl):1702-9. Epub 1993/02/15.
8. 8. Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87(3):287-94. Epub 2002/12/07.